keyword
https://read.qxmd.com/read/38532153/dynamic-treatment-strategy-of-chinese-medicine-for-metastatic-colorectal-cancer-based-on-machine-learning-algorithm
#1
JOURNAL ARTICLE
Yu-Ying Xu, Qiu-Yan Li, Dan-Hui Yi, Yue Chen, Jia-Wei Zhai, Tong Zhang, Ling-Yun Sun, Yu-Fei Yang
OBJECTIVE: To establish the dynamic treatment strategy of Chinese medicine (CM) for metastatic colorectal cancer (mCRC) by machine learning algorithm, in order to provide a reference for the selection of CM treatment strategies for mCRC. METHODS: From the outpatient cases of mCRC in the Department of Oncology at Xiyuan Hospital, China Academy of Chinese Medical Sciences, 197 cases that met the inclusion criteria were screened. According to different CM intervention strategies, the patients were divided into 3 groups: CM treatment alone, equal emphasis on Chinese and Western medicine treatment (CM combined with local treatment of tumors, oral chemotherapy, or targeted drugs), and CM assisted Western medicine treatment (CM combined with intravenous regimen of Western medicine)...
March 27, 2024: Chinese Journal of Integrative Medicine
https://read.qxmd.com/read/38526540/metastatic-colorectal-cancer-third-line-therapy-and-beyond
#2
REVIEW
Tiffany Foo, Amitesh Roy, Christos Karapetis, Amanda Townsend, Timothy Price
INTRODUCTION: The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing. METHOD: In this narrative review, we provide a comprehensive summary of data from key clinical trials and discuss how to integrate these agents into the current treatment landscape of metastatic colorectal cancer...
March 25, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38525371/efficacy-and-safety-of-maintenance-therapy-using-cetuximab-in-patients-with-metastatic-colorectal-cancer-retrospective-study
#3
JOURNAL ARTICLE
Tiantian Xuan, Zhanmei Wang, Sibo Meng, Jiaxin Li, Jisheng Li, Fangli Cao, Linli Qu
PURPOSE: Cetuximab (CET) combined with chemotherapy significantly improved the survival in RAS and RAF wild-type metastatic colorectal cancer (mCRC) patients, while clinical evidence was lacking on the use of maintenance therapy (MT). The study aimed to explore the role of maintenance therapy following Cetuximab + chemotherapy and the optimal Cetuximab-based maintenance therapy regimen. PATIENTS AND METHODS: We retrospectively reviewed data on the efficacy and safety of CET-based MT in patients with mCRC who achieved disease control after induction therapy...
2024: Cancer Management and Research
https://read.qxmd.com/read/38519391/ongoing-clinical-trials-and-future-research-scenarios-of-circulating-tumor-dna-for-the-treatment-of-metastatic-colorectal-cancer
#4
REVIEW
Laura Roazzi, Giorgio Patelli, Katia Bruna Bencardino, Alessio Amatu, Erica Bonazzina, Federica Tosi, Brunella Amoruso, Anna Bombelli, Sara Mariano, Stefano Stabile, Camillo Porta, Salvatore Siena, Andrea Sartore-Bianchi
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metastases, and have mainly focused on the genotyping of RAS and BRAF, that is propaedeutic for anti-EGFR treatment selection...
February 16, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38516270/co-inhibition-of-tgf-%C3%AE-and-pd-l1-pathways-in-a-metastatic-colorectal-cancer-mouse-model-triggers-interferon-responses-innate-cells-and-t-cells-alongside-metabolic-changes-and-tumor-resistance
#5
JOURNAL ARTICLE
Reshmi Nair, Tamsin R M Lannagan, Rene Jackstadt, Anna Andrusaite, John Cole, Caitlin Boyne, Robert J B Nibbs, Owen J Sansom, Simon Milling
Colorectal cancer (CRC) is the third most prevalent cancer worldwide with a high mortality rate (20-30%), especially due to metastasis to adjacent organs. Clinical responses to chemotherapy, radiation, targeted and immunotherapies are limited to a subset of patients making metastatic CRC (mCRC) difficult to treat. To understand the therapeutic modulation of immune response in mCRC, we have used a genetically engineered mouse model (GEMM), "KPN", which resembles the human 'CMS4'-like subtype. We show here that transforming growth factor (TGF-β1), secreted by KPN organoids, increases cancer cell proliferation, and inhibits splenocyte activation in vitro ...
2024: Oncoimmunology
https://read.qxmd.com/read/38503018/dynamic-ctdna-based-analysis-of-drug-resistant-gene-alterations-at-ras-braf-wild-type-metastatic-colorectal-cancer-patients-after-cetuximab-plus-chemotherapy-as-the-first-line-treatment
#6
JOURNAL ARTICLE
Yu-Wen Zhou, Xin Zhao, Lu Ni, Peng Cao, Wei-Bing Leng, Qing Zhu, Hong-Feng Gou, Jiao Zhang, Xiao-Fen Li, Meng Qiu
BACKGROUND: The purpose of this study was to explore the dynamic changes of genomic mutations and their correlations with the efficacy in metastatic colorectal cancer (mCRC) patients treated with cetuximab plus mFOLFOX as the first-line treatment. METHODS: We included mCRC patients from January 2018 to October 2020 as a studied cohort which were treated with cetuximab plus mFOLFOX as first line therapy. Blood samples were collected for circulating tumor DNA (ctDNA) test at three timepoints: before the first-line therapy(baseline), at the time of first-line progression and at the time of second-line progression...
March 18, 2024: International Immunopharmacology
https://read.qxmd.com/read/38502988/imaging-guided-prognostic-score-based-approach-to-assess-the-benefits-of-combotherapy-versus-monotherapy-with-immune-checkpoint-inhibitors-in-metastatic-msi-h-colorectal-cancer-patients
#7
JOURNAL ARTICLE
Rémy Barbe, Younes Belkouchi, Yves Menu, Romain Cohen, Clemence David, Michele Kind, Sana Harguem, Lama Dawi, Joya Hadchiti, Fatine Selhane, Nicolas Billet, Samy Ammari, Ambroise Bertin, Littisha Lawrance, Baptiste Cervantes, Antoine Hollebecque, Corinne Balleyguier, Paul-Henry Cournede, Hugues Talbot, Nathalie Lassau, Thierry Andre
BACKGROUND: This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. METHODS: One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts...
March 16, 2024: European Journal of Cancer
https://read.qxmd.com/read/38499079/understanding-the-role-of-dna-methylation-in-colorectal-cancer-mechanisms-detection-and-clinical-significance
#8
REVIEW
Ningning Zhao, Chuanxi Lai, Yunfei Wang, Sheng Dai, Hongcang Gu
Colorectal cancer (CRC) is one of the deadliest malignancies worldwide, ranking third in incidence and second in mortality. Remarkably, early stage localized CRC has a 5-year survival rate of over 90%; in stark contrast, the corresponding 5-year survival rate for metastatic CRC (mCRC) is only 14%. Compounding this problem is the staggering lack of effective therapeutic strategies. Beyond genetic mutations, which have been identified as critical instigators of CRC initiation and progression, the importance of epigenetic modifications, particularly DNA methylation (DNAm), cannot be underestimated, given that DNAm can be used for diagnosis, treatment monitoring and prognostic evaluation...
March 16, 2024: Biochimica et Biophysica Acta. Reviews on Cancer
https://read.qxmd.com/read/38497279/metabolism-toxicity-and-management-of-fruquintinib-a-novel-drug-for-metastatic-colorectal-cancer
#9
REVIEW
Kanchi Patell, Veronica Lee Mears, Michael H Storandt, Amit Mahipal
INTRODUCTION: Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) targeting VEGFR -1, -2, and -3, and has recently received approval by the U.S. Food and Drug Administration for treatment of mCRC refractory to standard chemotherapy, anti-VEGF therapy, and anti-epidermal growth factor receptor (EGFR) therapy...
March 18, 2024: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/38494801/-chemotherapy-for-unresectable-advanced-metastatic-or-recurrent-colorectal-cancer
#10
JOURNAL ARTICLE
Yu Miyashita, Akihito Kawazoe, Takayuki Yoshino
Colorectal cancer(CRC)is one of the most commonly diagnosed cancers worldwide. Unresectable advanced, metastatic or recurrent CRC(mCRC)remains incurable for most patients. Systemic chemotherapy is standard treatment for patients with mCRC. The goals of systemic chemotherapy include prolonging survival by stopping cancer progression and palliation. In recent years, advances in the treatment of mCRC have enabled personalized care based on the tumor's molecular profile with improved outcomes for some subtypes...
March 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38485190/modified-folfox6-plus-bevacizumab-with-and-without-nivolumab-for-first-line-treatment-of-metastatic-colorectal-cancer-phase-2-results-from-the-checkmate-9x8-randomized-clinical-trial
#11
JOURNAL ARTICLE
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy Larson, Eric Chen, Amit Mahipal, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell, Jin Yao, Josep Tabernero
BACKGROUND: Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with standard therapies in patients with mCRC. Here, we present phase 2 results of nivolumab plus standard-of-care therapy (SOC; 5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) versus SOC in the first-line treatment of patients with mCRC (CheckMate 9X8)...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38484194/efficacy-of-chemotherapy-rechallenge-versus-regorafenib-or-trifluridine-tipiracil-in-third-line-setting-of-metastatic-colorectal-cancer-a-multicenter-retrospective-comparative-study
#12
JOURNAL ARTICLE
Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Yasmin Tuleimat, Nashwa Abdel-Aziz, Mervat Mahrous, Sherif Elsamany, Tusneem Elhassan, Mohammed Alghamdi
PURPOSE: Metastatic colorectal cancer (mCRC) is a significant global health burden. This retrospective study compared the effectiveness of trifluridine/tipiracil (FTD/TPI), regorafenib, and chemotherapy rechallenge for third-line mCRC treatment. MATERIALS AND METHODS: We reviewed the medical records of 132 patients with mCRC treated with regorafenib, FTD/TPI, or a rechallenge with the initial chemotherapy regimen in a third-line setting from four different institutions...
March 2024: JCO global oncology
https://read.qxmd.com/read/38476223/effect-of-autologous-dendritic-cell-cytokine-induced-killer-on-refractory-metastatic-colorectal-cancer-a-matched-case-control-comparative-study
#13
JOURNAL ARTICLE
Sheng-Chi Chang, Tao-Wei Ke, William Tzu-Liang Chen, Weoi-Cherng Shyu, Long-Bin Jeng
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) who are refractory to two or more lines of systemic chemotherapy have limited therapeutic options. The aim of this study was to evaluate the effect of autologous dendritic cell cytokine-induced killer (DC-CIK) transfer on the survival of patients with mCRC who are refractory or intolerant to at least two lines of systemic chemotherapies. METHODS: A matched case-control comparative study was conducted with patients who received DC-CIK immunotherapy in addition to standard chemotherapy (cases) and those with standard chemotherapy alone (controls)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38473410/impact-of-primary-tumor-location-on-demographics-resectability-outcomes-and-quality-of-life-in-finnish-metastatic-colorectal-cancer-patients-subgroup-analysis-of-the-raxo-study
#14
JOURNAL ARTICLE
Sonja Aho, Emerik Osterlund, Ari Ristimäki, Lasse Nieminen, Jari Sundström, Markus J Mäkinen, Teijo Kuopio, Soili Kytölä, Annika Ålgars, Raija Ristamäki, Eetu Heervä, Raija Kallio, Päivi Halonen, Leena-Maija Soveri, Arno Nordin, Aki Uutela, Tapio Salminen, Hanna Stedt, Annamarja Lamminmäki, Timo Muhonen, Juha Kononen, Bengt Glimelius, Helena Isoniemi, Juho T Lehto, Kaisa Lehtomäki, Pia Osterlund
The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population ( n = 1080). Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kaplan-Meier, and Cox regression were used to compare the groups...
March 5, 2024: Cancers
https://read.qxmd.com/read/38473386/recent-advances-in-therapeutic-strategies-to-improve-colorectal-cancer-treatment
#15
REVIEW
William H Gmeiner
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC mortality results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy is often a preferred therapeutic option. Biomarker-based stratification of mCRC enables the use of precision therapy based on individual tumor mutational profiles. Activating mutations in the RAS/RAF/MAPK pathway downstream of EGFR signaling have, until recently, limited the use of EGFR-targeted therapies for mCRC; however, the development of anti-RAS and anti-RAF therapies together with improved strategies to limit compensatory signaling pathways is resulting in improved survival rates in several highly lethal mCRC sub-types (e...
March 2, 2024: Cancers
https://read.qxmd.com/read/38473349/focus-on-ras-codon-61-mutations-in-metastatic-colorectal-cancer-a-retrospective-analysis
#16
JOURNAL ARTICLE
Francesco Schietroma, Annunziato Anghelone, Giustina Valente, Viria Beccia, Giulia Caira, Alexia Spring, Giovanni Trovato, Armando Di Bello, Anna Ceccarelli, Laura Chiofalo, Serena Perazzo, Maria Bensi, Angelo Minucci, Andrea Urbani, Luigi Maria Larocca, Michele Basso, Carmelo Pozzo, Lisa Salvatore, Maria Alessandra Calegari, Giampaolo Tortora
RAS mutations involving codon 61 are rare in metastatic colorectal cancer (mCRC), accounting for only 1-4%, but they have recently been identified with high frequency in the circulating tumor DNA (ctDNA) of patients with secondary resistance to anti-EGFRs. This retrospective monocentric study aimed to investigate the clinical phenotype and prognostic performance of codon 61 RAS -mutated mCRC. Fifty patients with codon 61 RAS -mutated mCRC treated at our institution between January 2013 and December 2021 were enrolled...
February 29, 2024: Cancers
https://read.qxmd.com/read/38471288/trastuzumab-plus-pertuzumab-for-her2-amplified-advanced-colorectal-cancer-results-from-the-drug-rediscovery-protocol-drup
#17
JOURNAL ARTICLE
Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W J de Leng, Anne M L Jansen, Elske C Gootjes, Derk-Jan A de Groot, Emile D Kerver, Theo van Voorthuizen, Jeanine M L Roodhart, Liselot B J Valkenburg-van Iersel, Hans Gelderblom, Emile E Voest, Henk M W Verheul
BACKGROUND: In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third of these patients, it is not approved for this indication in Europe. In the Drug Rediscovery Protocol (DRUP), patients are treated with off-label drugs based on their molecular profile. Here, we present the results of the cohort 'trastuzumab/pertuzumab for treatment-refractory patients with RAS/BRAF-wild-type HER2amplified metastatic CRC (HER2+mCRC)'...
March 7, 2024: European Journal of Cancer
https://read.qxmd.com/read/38471240/impact-of-kras-g12-mutations-on-survival-with-trifluridine-tipiracil-plus-bevacizumab-in-patients-with-refractory-metastatic-colorectal-cancer-post%C3%A2-hoc-analysis-of-the-phase-iii-sunlight-trial
#18
JOURNAL ARTICLE
J Tabernero, J Taieb, M Fakih, G W Prager, E Van Cutsem, F Ciardiello, R J Mayer, N Amellal, D Skanji, E Calleja, T Yoshino
BACKGROUND: In metastatic colorectal cancer (mCRC), KRAS mutations are often associated with poorer survival; however, the prognostic impact of specific point mutations is unclear. In the phase III SUNLIGHT trial, trifluridine/tipiracil (FTD/TPI) plus bevacizumab significantly improved overall survival (OS) versus FTD/TPI alone. We assessed the impact of KRASG12 mutational status on OS in SUNLIGHT. PATIENTS AND METHODS: In the global, open-label, randomized, phase III SUNLIGHT trial, adults with mCRC who had received no more than two prior chemotherapy regimens were randomized 1 : 1 to receive FTD/TPI alone or FTD/TPI plus bevacizumab...
March 11, 2024: ESMO Open
https://read.qxmd.com/read/38451840/the-relationship-between-clinical-and-pathological-findings-and-fdg-pet-uptake-in-metastatic-colorectal-cancers
#19
JOURNAL ARTICLE
Bediz Kurt İnci, Fatih Gürler, Osman Sütcüoğlu, Gözde Tahtacı, Aytuğ Üner, Ahmet Özet, Nazan Günel, Ozan Yazıcı
BACKGROUND: In metastatic colorectal cancer (mCRC), the genetic structure and cell metabolism of the primary tumor lesion might be different from metastatic lesions. It is thought that cell-level glucose metabolism may differ due to the difference in RAS wild and mutant mCRC patients' prognosis. In this study, we aimed to compare 2-deoxy-2-[fluorine-18]-fluoro-D-glucose Positron Emission Tomography (18F-FDG PET/CT) uptake levels for KRAS mutation status and primary-metastatic tumor localization...
March 1, 2024: Indian Journal of Cancer
https://read.qxmd.com/read/38451823/twelve-month-progression-free-survival-with-sotorasib-and-panitumumab-in-kras-g12c-mutant-metastatic-colorectal-cancer
#20
JOURNAL ARTICLE
Gozde Kavgaci, Omer Dizdar, Suayib Yalcin
Colorectal cancer (CRC) ranks third in global cancer prevalence, with 40% presenting as metastatic colorectal cancer (mCRC). KRAS mutations in mCRC patients confer resistance to anti-EGFR treatments. Promising inhibitors such as sotorasib and adagrasib targeting KRASG12C mutations have demonstrated efficacy. Herein, we present a heavily pretreated mCRC case with a progression-free survival of 12 months with sotorasib and panitumumab. In 2017, a 27-year-old male presented with abdominal pain and received a diagnosis of stage IIIC KRAS G12C mutant CRC...
March 5, 2024: Anti-cancer Drugs
keyword
keyword
37091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.